[Canniseur: Mr. Klare has rightfully called out CNN on this. Obviously, the person at CNN who wrote the story either didn’t know or understand that cannabis is cannabis whether it’s medical or adult use. Strange that CNN would even do this story as it’s filled with so many inaccuracies and innuendos that it barely qualifies as news. I thought we were past these sensationalist kinds of stories, but apparently, I’m wrong. The editors at CNN should be ashamed.]
As many of you know, much of my day is spent perusing news related to cannabis. Much of what I opine on and analyze is pretty straightforward news, but sometimes I will use this space to rebut an opinion piece I disagree with.
But there are rare occasions where something is so weirdly constructed and misleading that I feel compelled to point it out.
Today’s installment is an article from CNN entitled “Weed impairs driving skills long after the high is gone.” My first thought was that since THC content in blood can in no way point to impairment, this will be some sort of attempt to claim that THC in blood is accurate after all, since you are still “impaired” long after you are no longer high.
The study in question used a driving simulator and looked at “heavy users”, which was “defined by daily or near daily use, a minimum of four or five times a week, with a lifetime exposure of 1,500 times.” After 12 hours of non-use for users who were “based on urine tests…not intoxicated on THC”, whatever that means, it was shown that heavy users still drive much worse than non-users, the worst results coming from heavy users who started before the age of 16.
Staci Gruber, director of the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital, opines that early marijuana use negatively affects the part of the brain responsible for cognitive performance and impulse control. The discussion of impulse control is immediately followed by this little nugget:
Does this same concern apply to users of medicinal marijuana? Not at all, Gruber says.
“In our medical cannabis patients we don’t see that at all. We actually see improvements,” she said.
I have to admit, I’m stumped here. Is she saying that people having what they deem as medical problems means that marijuana helps with impulse control? After all, recreational and medical marijuana users are consuming the same marijuana. The marijuana isn’t different depending on the reason the person who is consuming it says they need it or whether or not their stated ailment happens to be a qualifying condition in the state they live in.
How could the same marijuana have a completely different effect, depending on whether or not the user lands in the very subjective “medical” category? And what if a different state deems other conditions as qualifying? Would someone going from state to state have the cannabis affect them differently depending on their medical status in the eyes of the law?
In the end, we are talking about one study versus many others that have shown that cannabis has minimal effects on driving. Even the study authors caution – as they all do – that more research needs to be done.
Of course, no one is advocating for people to get high and drive. But we also can’t be hysterical about it and must look for ways to minimize whatever risk there may be.
[Canniseur: Are we surprised? Is it because the CBD industry is unregulated? Is it because there are scam artists who are looking to make a quick buck? Even if the story is about pet CBD, human CBD products have the same issues. CBD products need regulation and testing that can be trusted.]
Companies have unleashed hundreds of CBD pet health products accompanied by glowing customer testimonials claiming the cannabis derivative produced calmer, quieter and pain-free dogs and cats.
But some of these products are all bark and no bite.
“You’d be astounded by the analysis we’ve seen of products on the shelf with virtually no CBD in them,” said Cornell University veterinary researcher Joseph Wakshlag, who studies therapeutic uses for the compound. “Or products with 2 milligrams per millilitre, when an effective concentration would be between 25 and 75 milligrams per millilitre. There are plenty of folks looking to make a dollar rather than produce anything that’s really beneficial.”
Such products can make it to the shelves because the federal government has yet to establish standards for CBD that will help people know whether it works for their pets and how much to give.
Still, there’s lots of individual success stories that help fuel a $400 million market that grew more than tenfold since last year and is expected to reach $1.7 billion by 2023, according to the cannabis research firm Brightfield Group.
Amy Carter of St. Francis, Wisconsin, decided to go against her veterinarian’s advice and try CBD oil recommended by a friend to treat Bentley, her epileptic Yorkshire terrier-Chihuahua mix. The little dog’s cluster seizures had become more frequent and frightening despite expensive medications.
“It’s amazing” Carter said. “Bentley was having multiple seizures a week. To have only six in the past seven months is absolutely incredible.”
But some pet owners have found CBD didn’t work.
Dawn Thiele, an accountant in Oak Creek, Wisconsin, said she bought a $53 bottle of CBD oil from a local shop in hopes of calming her 2-year-old Yorkshire terrier during long car trips.
“I didn’t see a change in his behaviour,” said Thiele, who nonetheless remains a believer.
“The product is good, it just didn’t work for my dog,” she said.
Short for cannabidiol, CBD is a non-intoxicating molecule found in hemp and marijuana. Both are cannabis plants, but only marijuana has enough of the compound THC to get users high. The vast majority of CBD products come from hemp, which has less than 0.3% THC.
CBD has garnered a devoted following among people who swear by it for everything from stress reduction to better sleep. Passage of the 2018 Farm Bill, which eased federal legal restrictions on hemp cultivation and transport, unleashed a stampede of companies rushing products to the market in an absence of regulations ensuring safety, quality and effectiveness.
Products for people were swiftly followed by CBD chewies, oils and sprays for pets.
“The growth is more rapid than I’ve seen for any product in 20 years in this business,” said Bill Bookout, president of the National Animal Supplement Council, an industry group whose member companies agree to testing and data-gathering requirements. “There’s a gold rush going on now. Probably 95 per cent of the industry participants are responsible, but what’s dangerous is the fly-by-night operative that wants to cash in.”
The U.S. Food and Drug Administration is developing regulations for marketing CBD products, for pets or people. This year, it has sent warning letters to 22 companies citing violations such as making claims about therapeutic uses and treatment of disease in humans or animals or marketing CBD as a dietary supplement or food ingredient.
“It’s really the Wild West out there,” said S. David Moche, founder of Applied Basic Science, a company formed to support Colorado State University’s veterinary CBD research and now selling CBD online. He advises consumers to look for a certificate of analysis from a third-party testing laboratory to ensure they’re getting what they pay for.
“Testing and labeling is going to be a critical part of the future of this industry,” Moche said.
Wakshlag said products must be tested not only for CBD level, but also to ensure they’re free of toxic contaminants such as heavy metals and pesticides and have only trace amounts of THC, which in higher levels is toxic to dogs.
Bookout said his organization has recorded very few health incidents involving CBD and no deaths.
Still, scientific documentation of CBD’s safety and efficacy is nearly nonexistent.
That’s starting to change, however. A small clinical trial at Colorado State University published in the Journal of the American Veterinary Medical Association in June found CBD oil reduced seizure frequency in 89 per cent of the epileptic dogs that received it.
A clinical study headed by Wakshlag at Cornell, published in Frontiers in Veterinary Science in July 2018, found CBD oil helped increase comfort and activity in dogs with osteoarthritis.
Stephanie McGrath, a Colorado State University researcher, is now doing a larger clinical trial funded by the American Kennel Club’s Canine Health Foundation.
“The results of our first epilepsy study were promising, but there was certainly not enough data to say CBD is the new miracle anti-convulsive drug in dogs,” McGrath said.
Seizures are a natural focus for research on veterinary CBD products, since Epidiolex, the only FDA-approved drug containing cannabidiol, was approved last year for treatment of two severe forms of epilepsy in children. Veterinarians are allowed to prescribe Epidiolex for pets, but it’s prohibitively expensive — upwards of $30,000 a year for an average-size dog, McGrath said.
The Kennel Club’s chief veterinary officer, Jerry Klein, said CBD is “over-hyped” but promising for treatments like pain relief. He’s hopeful that the growing market will result in more money being invested in research to prove uses.
Meantime, the American Veterinary Medical Association is telling veterinarians they can share what they know about CBD with clients but shouldn’t prescribe or recommend it until the FDA gives its blessing.
“There’s no question there’s veterinary interest in these products as therapies, but we really want to see the manufacturers demonstrate that they’re effective and safe and get FDA approval so we can have confidence in the products,” said Gail Golab, chief veterinary officer for the association.
[Canniseur: The cannabis industry needs more research. Lots more research. All the research of cannabis over the past 10 years is elementrary. The elementary research needs to be built upon with more complex avenues of research. More research won’t happen until the Federal government changes its policies about cannabis and removes it from Category 1. Not even opiates (except heroin) are Category 1. This is during an epidemic of opiate overdose deaths. The only way there will be more research and pertinent research is to get the government to reschedule cannabis.]
The head of the top federal medical research agency said in a new interview that marijuana’s status as a Schedule I drug inhibits studies into the plant and prevents scientists from researching the effects of cannabis that consumers are obtaining from state-legal dispensaries in a growing number of states.
Francis Collins, director of the National Institutes of Health (NIH), discussed the limitations imposed by the federal drug scheduling system during an appearance on C-SPAN’s Newsmakers that aired last week, saying that while he shares concerns about the potential health implications of smoking marijuana, research into the risks and benefits of cannabis is being impeded by current policy.
“Frankly, we know far too little about the benefits and risks of smoked marijuana,” Collins said. “There have been very few studies that have actually rigorously tested that.”
The director said scientists are in a “funny place” in the U.S. when it comes to cannabis, noting that in order to use federal funds to research the plant and its compounds, the products must come from a single source: a government-authorized farm at the University of Mississippi that cultivates marijuana that’s been widely criticized for lacking the properties associated with cannabis that’s commercially available in state markets.
“People don’t realize that I run a farm in Mississippi that grows marijuana because I’m required to do so,” Collins said, referring to the facility that’s licensed by the National Institute on Drug Abuse (NIDA), which is part of NIH. “But that’s the only source that investigators can use, and it may be rather different than what you could get in one of the states where marijuana is now approved in terms of its constituents.”
“It’s going to be very hard to interpret data about smoked marijuana when the actual nature of the product is vastly different depending on where you got it” with respect to properties like THC and CBD content, he said.
“We’d really like to have studies where you’re studying those compounds in pure form so you can see what they’re doing,” he said. “But again because of various limitations of Schedule I limits, we are not able to do as much as we would like.”
Another “big deterrent” to research is the extensive series of hurdles that scientists must overcome to receive approval to study marijuana, Collins said. Researchers must be cleared by the Drug Enforcement Administration (DEA) and also submit an investigational new drug application to the Food and Drug Administration in order to conduct cannabis-involved clinical studies on humans.
The discussion on C-SPAN about scientific limitations came in response to a question about whether the marijuana industry is exerting any influence over federally approved research initiatives. While NIH faced criticism in 2018 over its handling of a study into potential benefits of moderate alcohol consumption because alcohol interests were actively engaging in the study process, Collins said the scientific community is not experiencing that kind of influence from cannabis businesses.
“I would not say at the present time that industry is attempting really to influence a lot of what we’re doing in the marijuana area,” he said, adding that NIH is currently putting about $150 million into marijuana research projects.
This post, a video from 60 Minutes Australia shows the heartbreaking story about grandparents working to help their granddaughter who has an intractable form of epilepsy that would kill her without cannabis. It doesn’t tell whether it’s CBD or a THC derivative, but it’s important. The Australians seem to be behind even the U.S. when it comes to the medical uses of cannabis. This is helping the little girl, but her father has been under arrest. Somehow it’s inhumane of the Australian government to pursue it any farther.
[Canniseur: All psychoactive drugs found in nature (and some not) have uses for people. I get it that there are diseases like depression that might be helped by psychoactive compounds. But diabetes? WOW! And it appears that many other disorders can be helped…maybe. Since there’s no real research, it remains to be seen if psilocybin can be useful therapy for disease. The potential could be great.]
Could the key ingredients in psychedelic mushrooms promote weight loss, healthier dietary choices, and prevent the onset of type 2 diabetes? That’s what one Canadian company is claiming in a new US patent filing.
The patent, filed by Yield Growth’s American subsidiary, Flourish Mushroom Labs, details a recipe for making a pill from psilocybin and psilocin, two shroom compounds responsible for making humans (and some animals) trip. The pill itself only includes microdosed amounts, or roughly a tenth of the so-called “recreational dose,” so anyone who takes it shouldn’t see their food breathing or their wallpaper designs coming to life…
[Canniseur: Interesting question with a lot of variables. Maybe too many to be definitive. There is such a thing as too much cannabis, but the reaction is usually paranoia or anxiety. Nobody has ever died from too much cannabis. But you can feel pretty miserable for a few hours. You can find out here parts of the very slippery equation how long does the buzz last.]
How long does a marijuana high last? What if it’s from an edible? Or a vape? We answer all of your questions. Check out the definitive guide on High Times.
Why Worry How Long Your Weed High Will Last?
Maybe things aren’t as dire as I’m imagining. Maybe you need to get behind the wheel eventually and want to know how long you should wait to drive. Perhaps you just want to know what kind of experience to expect from different cannabis products and delivery methods.
Perhaps you’re thinking strategically: that awesome band goes on at 10 p.m. and you want to plan your session before they hit, so you peak when they rock your favorite track. Or maybe you’re a medical patient who wants to leave space in the day for your treatment without compromising your productivity.
After all, there are all kinds of reasons you might be asking yourself “how long does a marijuana high last?” If you have some experience with weed, you probably already have a sense of how long your high sticks around. But you might still want to know how you can take control over that aspect of your experience.
And if you’re relatively new to cannabis, having an authoritative answer is an important part of making sure you have an enjoyable session. For everyone who enjoys cannabis, timing, as they say, is everything.
How Long Does A High Last? Use the “Highness Equation” to Find Out
It might not get past the peer review board of a medical journal, but here’s a more-or-less scientific way to “calculate” how long you can expect your weed high to last. Call it the “highness equation.”
The highness equation incorporates the four major aspects that determine how long your marijuana high will last. Here it is:
Length of High = ( (dose x concentration) / (metabolism x tolerance) ) x delivery method
So that’s the dose you take multiplied by the concentration of the product, divided by your metabolism times your tolerance, all multiplied by the delivery method factor: ingestion or inhalation.
In other words: how much weed you put in your body, divided by how your body processes and responds, all shaped by the specific path the weed takes through your system.
It’s less complicated than it sounds. And if you’re looking for a bottom line answer—the median, the average, the “ballpark,” then your answer is simple.
After you get high from inhaling weed, expect to stay high for about one to two hours. If you’ve eaten your cannabis, your high will last about 3 to 4 hours, maybe longer.
But if the tl;dr version doesn’t satisfy, read on to find out the factors that influence how long your high lasts. Then, once you figure out where you fall, you can start experimenting with ways to prolong, or if need be, shorten your high.
William Casey/ Shutterstock
Your High Lasts As Long As THC Meets Up With Your Endocannabinoid System
But that doesn’t mean you necessarily feel high. And there’s the crux of the question. Your “high” is the sum of an infinitely complex series of metabolic and chemical reactions occurring all throughout your body.
Whether we perceive the effects of those reactions depends on their intensity and our sensitivity to them. And that’s why you’ll find studies claiming that the effects of cannabis can last from 5 hours up to a full day.
That may be true on a chemical level. But THC can interact with our bodies without giving us the experience of feeling high, especially at low levels.
And that’s where the bottom of our “highness equation” comes in: metabolism x tolerance. Being on the bottom of the equation means these are the factors that work against your high, shortening how long you feel the effects of THC.
Metabolism x Tolerance
There’s a common misconception that a person’s weight determines how high they get and how long that high will last. But in fact, it’s a person’s metabolism that plays a major role in the length of a high.
The length of your high depends on the presence of THC in your bloodstream. Your blood carries that THC to the network of cell receptors it binds to, the endocannabinoid system (ECS).
Your body is also in the business of metabolizing the stuff you put into it, breaking it down, taking what it needs, and expelling the rest.
So if you’ve got a high metabolism, your highs will tend to be shorter. Or at least, your body is working against the clock a little bit.
Then, there’s that elusive and hard-to-quantify factor of tolerance. In common parlance, we say we have a high or low tolerance to weed. But in reality, what we mean is that we have a higher or lower tolerance to the dopamine and other neurotransmitters our brain releases when THC meets up with the ECS.
The good news is, cannabis doesn’t so thoroughly deplete our dopamine supplies that we have to chase ever larger quantities to get the same effect.
But that also means THC’s powers are limited. Hence the ceiling effect frequent users experience, where no matter what they do, they can’t get higher than a certain point. If you’re hitting that ceiling, the answer to the question “how long does a high last?” is probably not long enough.
For most regular cannabis users, however, the same dose will produce roughly the same experience time after time. For heavy users, even a short “tolerance break” can restore your tolerance levels to their low defaults, making your next high feel more like your first.
However, if you’ve built up a tolerance over time or with frequent use, your high is going to feel shorter for sure.
If You Want a Longer High, Consider Upping Your Dosage or Using Higher-Potency Products
Now that we’ve covered what shortens the length of your high, let’s look at what extends it. This is definitely the simpler part of the equation.
Put more weed into your system, and in all likelihood, you’re going to have a longer high. That means smoking strains with higher THC concentrations. Or vaping concentrates—or even better distillates, with upwards of 85 percent THC.
It also means taking a larger dose. Not only will your high last longer, it will stretch out your peak so you enjoy your high as long as your body allows. How long does a high last for you if you smoke flower versus vape concentrates?
How Long Does A High Last: Calculating Dose x Concentration
The top of our highness equation is pretty self-explanatory. But a few points bear repeating.
If you’re new to cannabis, it’s really a good idea to start with smaller doses. Don’t feel like you have to take huge rips or smoke multiple bowls just because the other kids are doing it. If you want that, you’ll get there in due time.
For now, appreciate what you have, that veteran weed enthusiasts often sorely miss: those early, heady days when a single puff sent you to outer space. (Maybe that’s part of what drives dabbing culture: that desire to recreate those first encounters with weed—that inimitable intensity and euphoria.)
The rest of us are busy chasing that dragon with ever-higher concentrations and tech that makes huge doses possible. Rip a 2-gram dab in one sitting and you’ll be high for the better part of the day, probably. Rip 20 grams and you’ll probably feel high for the rest of the week.
So when it comes to dosage, that’s easy. Smoke or vape more for a longer high. Even better, spread out your sessions. That will keep tossing you back up to the peak of your high when you’re on your way down.
And in terms of concentration, look for high-THC strains and strains with ultra-low CBD. (CBD can counterbalance the effects of THC on your system, shortening your high.) Or just stick with concentrates and extracts.
Canna Obscura/ Shutterstock
The Delivery Method Factor: Inhale or Eat?
We’ve covered all the parts of the highness equation. Except for the one that shapes them all: delivery method.
Those who’ve tried them know that edibles tend to produce a much longer-lasting high than inhalation methods.
That’s because of the metabolic pathway that THC takes through your body when you eat it versus when you inhale it. To make a long story short, your digestive tract converts THC into a different active form than heating alone.
How long does a high last from consuming edibles? Well that form, THC-COOH, or carboxy-THC, has some serious staying power. But your body takes some time to produce it. That’s why you have to wait 45 minutes to an hour or so for an edible to really kick in.
Once that THC-COOH is pumping through your bloodstream, you’re along for the ride until your body is finished processing it. Again, that can be about three to four hours on average and sometimes longer.
So for those truly looking for an extended high experience and who have the patience for an edible or drinkable cannabis product to kick in, ingesting your weed is the way to go.
How Long Does A Weed High Last For You? Your Mileage May Vary
How long does a weed high last if you eat your cannabis? How long does a marijuana high last if you smoke flower? Just generally, how long does a high last? If you’ve come away with anything from this article, hopefully it’s an appreciation for the complex chemical dance that is a weed high, and all the factors that make up the answer to those questions.
Of course, there’s no definite, constant answer. The lengths of your own highs will change. No need to compare them to other folks’.
So, how long does a high last for you? If you plan on one to two hours for inhaled cannabis and three to four with ingested weed, longer with higher doses and concentrations and shorter with higher metabolisms and tolerances, you’ll be all set.
[Updated from a post originally published in July, 2018]
[Canniseur: One thought comes to mind; How anyone might mistake a placebo with a weed high? Seriously though, this is such great news. While not the first cannabis study at Yale, I love hearing about scientific cannabis studies. In 3-5 years, we’ll see some results. Let the validations begin!]
The US Food and Drug Administration (FDA) has just given the Yale University School of Medicine approval to begin clinical trials that could pave the way for the first American-made cannabis-based treatment for pain and stress.
The new study, which was also approved by the Connecticut Department of Consumer Protection, will research how different strains of medical cannabis could be used to alleviate chronic pain or stress. The study may also explore how and if pot can help treat other conditions like PTSD, or to help individuals wean themselves off of opioids. This is one of the first FDA-approved double-blind studies on medical marijuana to be conducted on humans.
Rather than relying on the low-quality “ditch weed” that the US government provides to researchers, Yale will be partnering with CT Pharmaceutical Solutions Inc., a medical cannabis producer based in Portland, Connecticut. CT Pharma has been working on this study in partnership with Yale’s Dr. Rajita Sinha since 2016, but it’s taken three years to receive all of the necessary regulatory approvals to begin the trial.
“With increasing levels of use of medical marijuana products in the US today, it is imperative that we understand the science of how these products are working to alleviate patient symptoms,” said Sinha in a press release, according to the Hartford Business Journal. The new study intends to explore “how medical marijuana may alleviate pain and stress symptoms and contribute to developing new cannabinoid based treatments.”
In the first phase of the trial, researchers will recruit recreational cannabis users between the ages of 21 and 45 who do not qualify for Connecticut’s medical marijuana program. In the second phase, the subject pool will include adults aged 21 to 60 who are suffering from chronic pain. Subjects in both phases of the trial will randomly receive either THC, CBD, or a placebo. In addition to observing the effects of these cannabinoids on pain and other conditions, researchers will monitor the subjects’ heart rate, blood pressure, and other vital signs.
Gallery — These Athletes Believe in the Power of Medical Cannabis
CT Pharma board chair Michael Fedele said that if these trials are successful, his company intends to bring this new cannabis medicine to market in the US.
“Right now, a company in England has the only FDA-approved, plant-based medical marijuana product in our market,” said Fedele, according to the Connecticut Mirror. “That really shouldn’t be the case with respect to American companies.”
In order to approve the drug for the US market, the FDA would require another round of trials, which could take another 3 to 7 years. But if all of these trials succeed, doctors anywhere in the US would be legally able to prescribe this cannabis product to their patients, even in states that do not have medical marijuana programs.
[Canniseur: An effective treatment for endometriosis is of interest to many, many women. Cannabis as an answer makes sense. The endocannabinoid system (ECS) is one of the body’s primary regulatory systems. The female reproductive system includes a large number of cannabinoid receptors. These can be directly affected by the consumption of cannabinoids like THC or CBD.]
An Australian study found that women rate cannabis as the most effective treatment for endometriosis. But many have been forced to buy this medicine on the black market, thanks to strict marijuana laws.
Medical cannabis is one of the most effective treatments for symptoms of endometriosis, according to a new study recently published in the Journal of Obstetrics and Gynaecology Canada (JOGC).
This study surveyed 484 Australian women between the ages of 18 and 45 who have been surgically diagnosed with endometriosis — a chronic, inflammatory condition that affects about ten percent of all women of reproductive age. Endometriosis can cause pain, infertility, and gastrointestinal issues. Many women report that they still struggle with these symptoms even after having surgery or taking traditional medications.
The participants were asked whether they used self-management techniques to treat symptoms of their illness that are not utilized by traditional medication. Further questions investigated what kinds of self-management techniques were being used, how well these techniques worked, and if there were any negative side effects associated with self-management.
The study reports that 76 percent of all respondents said they used self-management techniques in the past six months. Most of the respondents (70 percent) used heat packs to treat their symptoms, but others turned to dietary changes (44 percent), exercise (42 percent), yoga and pilates (35 percent), or cannabis (13 percent). Yet although cannabis was the least popular self-management choice, women who used it rated it as the most effective technique.
“Women report good efficacy of cannabis in reducing pain and other symptoms, with few adverse effects reported,” the study authors wrote. Subjects who reported higher levels of pain were more likely to use cannabis than those suffering from milder symptoms. Women who used cannabis also reported a decrease in gastrointestinal problems, nausea, anxiety, depression, and insomnia. About ten percent of cannabis users did report minor side effects, including drowsiness, anxiety, and accelerated heart rate.
Researchers believe that cannabis may be able to reduce symptoms of endometriosis by way of the endocannabinoid system (ECS). The ECS is one of the body’s primary regulatory systems, controlling metabolism, inflammation, immune function, and many other biological systems. It is known that the female reproductive system includes a large number of cannabinoid receptors, which can be directly affected by the consumption of cannabinoids like THC or CBD.
Australian doctors are currently able to prescribe medical cannabis via regulated pathways that allow limited use of unapproved medicines. But in 2017, when this survey was administered, this type of access did not exist, and women participating in the survey were likely using weed procured from black market sources to treat their symptoms. This limits the findings of the study, as researchers do not know what kinds of cannabis products the women were using, or their potency.
“Australian law currently requires legal medicinal cannabis use to follow specific, regulated pathways that limit prescription by this method; however, self-reported illicit use of cannabis remains relatively common in Australian women with endometriosis,” the researchers concluded. “Further clinical research is warranted to determine the effectiveness of cannabis in managing endometriosis symptoms. In locations where medicinal cannabis is more accessible, there remains a paucity of evidence for its clinical efficacy with endometriosis-associated symptoms.”
One thing to keep in mind is that the illegality of cannabis in Australia at the time of the study likely impacted the figures in this report. As legalization in the West has shown, people are more comfortable being truthful about their marijuana consumption when it is legal. It’s possible (read: likely), then, that far more than 13 percent of Austrailian women with endometriosis medicate with cannabis to help cope with the pain and discomfort caused by the condition.